Daniel P. Petrylak - Publications, H-index & Citations

Daniel P. Petrylak

yale

87H指数

829论文数

4.5W被引数

收录论文 161

发表时间

20 years of taxane therapy in prostate cancer — the past, present and future 20年紫杉烷类药物治疗前列腺癌——过去、现在与未来

Nature Reviews Urology

IF14.6

2025-11-10

PREAI

Marc Carceles-Cordon; Veronica Rodriguez-Bravo; Daniel P. Petrylak; Josep Domingo-Domenech

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy TROPHY-U-01研究（队列2）的通俗总结：在无法接受顺铂为基础化疗的转移性尿路上皮癌患者中，免疫疗法后使用sacituzumab govitecan的疗效。

FUTURE ONCOLOGY

IF2.6

2025-09-01

OAAI

Grivas, Petros; Tagawa, Gurdeep; Jain, Rohit K.; Bupathi, Manojkumar; Balar, Arjun; Rezazadeh Kalebasty, Arash; George, Saby; Palmbos, Phillip; Nordquist, Luke; Petrylak, Daniel P.; Davis, Nancy; Sternberg, Cora N.; Agarwal, Neeraj; Park, Chandler; Tonelli, Julia; Zhou, Huafeng; Bangs, Rick; Loriot, Yohann

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease 阿维鲁姆单抗一线维持治疗晚期尿路上皮癌：来自JAVELIN Bladder 100试验中非内脏或仅淋巴结疾病患者的长期结局

European Urology

IF25.2

2025-06-03

OAAI

Joaquim Bellmunt; Thomas Powles; Se Hoon Park; Eric Voog; Begona P. Valderrama; Howard Gurney; Anders Ullén; Yohann Loriot; Srikala S. Sridhar; Norihiko Tsuchiya; Cora N. Sternberg; Jeanny B. Aragon-Ching; Daniel P. Petrylak; Miguel A. Climent Duran; Karin Tyroller; Jason Hoffman; Natalia Jacob; Petros Grivas; Shilpa Gupta

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study 恩诺单抗维多汀联合帕博利珠单抗对比化疗在先前未经治疗的局部晚期或转移性尿路上皮癌患者中的疗效（EV-302）：一项开放标签、随机对照、III期研究的患者报告结局

lancet oncology

IF0

2025-05-28

PREAI

Shilpa Gupta; Yohann Loriot; Michiel S Van der Heijden; Jens Bedke; Begoña P Valderrama; Eiji Kikuchi; Aude Fléchon; Daniel Petrylak; Maria De Santis; Matthew D Galsky; Jae Lyun Lee; Umang Swami; Srikala S Sridhar; Ugo De Giorgi; Phoebe Wright; Vanessa Shih; Yi-Tsung Lu; Xuesong Guan; Ryan Dillon; Aditya Shetty; Blanca Homet Moreno; Jennifer L Beaumont; Intan Purnajo; Shauna McManus; Thomas Powles

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer KEYNOTE-921研究中患者报告结局：帕博利珠单抗联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌

European Urology Oncology

IF9.3

2025-05-13

PREAI

Nobuaki Matsubara; Daniel Petrylak; Raffaele Ratta; Ernesto Korbenfeld; Rustem Gafanov; Loïc Mourey; Tilman Todenhöfer; Howard Gurney; Gero Kramer; Andries M. Bergman; Pawel Zalewski; Maria De Santis; Andrew J. Armstrong; Winald Gerritsen; Russell K. Pachynski; Todd L. Saretsky; Sameer R. Ghate; Fan Wang; Charles Schloss; Karim Fizazi

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients Avelumab一线维持治疗晚期尿路上皮癌：JAVELIN Bladder 100试验中老年患者长期结局

ESMO OPEN

IF8.3

2025-04-01

PREAI

Gupta, S.; Duran, M. A. Climent; Sridhar, S. S.; Powles, T.; Bellmunt, J.; Park, S. H.; Gurney, H.; Tsuchiya, N.; Petrylak, D. P.; Tomita, Y.; di Pietro, A.; Manitz, J.; Tyroller, K.; Hoffman, J.; Jacob, N.; Grivas, P.

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial 阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

ESMO OPEN

IF8.3

2024-12-01

PREAI

Rosenberg, J. E.; Galsky, M. D.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; van der Heijden, M. S.; Dreicer, R.; Duran, I.; Castellano, D.; Drakaki, A.; Retz, M.; Sridhar, S. S.; Grivas, P.; Yu, E. Y.; O'Donnell, H.; Burris, H. A.; Mariathasan, S.; Shi, Y.; Goluboff, E.; Bajorin, D.

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 对患有生物化学复发和晚期前列腺癌的男性实施循证策略: 来自美国前列腺癌会议2024的共识建议

CANCER

IF5.1

2024-12-01

PREAI

Bryce, Alan H.; Agarwal, Neeraj; Beltran, Himisha; Hussain, Maha H.; Sartor, Oliver; Shore, Neal; Antonarakis, Emmanuel S.; Armstrong, Andrew J.; Calais, Jeremie; Carducci, Michael A.; Dorff, Tanya Barauskas; Efstathiou, Jason A.; Gleave, Martin; Gomella, Leonard G.; Higano, Celestia; Hope, Thomas A.; Iagaru, Andrei; Morgans, Alicia K.; Morris, David S.; Morris, Michael J.; Petrylak, Daniel P.; Reiter, Robert E.; Rettig, Matthew B.; Ryan, Charles J.; Sellinger, Scott B.; Spratt, Daniel E.; Srinivas, Sandy; Tagawa, Scott T.; Taplin, Mary-Ellen; Yu, Evan Y.; Zhang, Tian; Mckay, Rana R.; Koo, Phillip J.; Crawford, E. David

A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up 一类口服先天免疫激活剂BXCL701联合帕博利珠单抗治疗转移性去势抵抗性前列腺癌（mCRPC）患者的II期研究：长期随访

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Aggarwal, R.; Tagawa, S. T.; Monk, P.; Zhu, X.; Jones, R. J.; Linch, M.; Costin, D.; de Bono, J. S.; Karsh, L. I.; Petrylak, D. P.; Borderies, P.; Deshpande, R.; O'Neill, V.; Zhang, J.

Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) plus pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)研究EV-103剂量递增/队列A（DE/A）：在不可接受顺铂治疗的局部晚期或转移性尿路上皮癌（la/mUC）中，恩沃利单抗偶联物（EV）联合帕博利珠单抗（P）的一线（1L）5年随访研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; Brown, J. R.; McKay, R. R.; Merchan, J. R.; Srinivas, S.; Shetty, A.; Homet Moreno, B.; Davis, G.; Wirtz, H.; Zhu, Y.; Milowsky, M. I.

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial 在接受第二线帕博利珠单抗治疗的尿路上皮癌患者中，先前化疗对疗效的影响：KEYNOTE-045 III期试验的探索性分析

European Urology

IF25.2

2024-08-22

PREAI

Ronald de Wit; David J. Vaughn; Yves Fradet; Lawrence Fong; Miguel A. Climent; Andrea Necchi; Daniel P. Petrylak; Winald R. Gerritsen; Howard Gurney; David I. Quinn; Stéphane Culine; Cora N. Sternberg; Dean F. Bajorin; Toni K. Choueiri; Jin Xu; Kentaro Imai; Blanca Homet Moreno; Joaquim Bellmunt; Jae-Lyun Lee

EUROPEAN UROLOGY

IF25.2

2024-06-01

OAAI

Rosenberg, Jonathan E.; Mamtani, Ronac; Sonpavde, Guru P.; Loriot, Yohann; Duran, Ignacio; Lee, Jae-Lyun; Matsubara, Nobuaki; Vulsteke, Christof; Castellano, Daniel; Sridhar, Srikala S.; Pappot, Helle; Gurney, Howard; Bedke, Jens; van der Heijden, Michiel S.; Galli, Luca; Keam, Bhumsuk; Masumori, Naoya; Meran, Johannes; O'Donnell, Peter H.; Park, Se Hoon; Grande, Enrique; Sengelov, Lisa; Uemura, Hiroji; Skaltsa, Konstantina; Campbell, Mary; Matsangou, Maria; Wu, Chunzhang; Hepp, Zsolt; Mckay, Caroline; Powles, Thomas; Petrylak, Daniel P.

ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NAïVE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY

JOURNAL OF UROLOGY

IF6.8

2024-05-01

PREAI

Shore, Neal; Lang, Joshua M.; Geynisman, Daniel M.; Stewart, Tyler F.; Gao, Xin; Appleman, Leonard J.; Dreicer, Robert; Dorff, Tanya; Berghorn, Elmer; Duperret, Elizabeth; Lu, Haolan; Chan, Edward; Garmezy, Benjamin; Petrylak, Daniel P.

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinumbased chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes TROPHY-U-01，sacituzumab govitecan用于铂化疗和检查点抑制剂后进展的转移性尿路上皮癌患者的II期开放标签研究: 更新的安全性和有效性结果

ANNALS OF ONCOLOGY

IF65.4

2024-04-01

OAAI

Loriot, Y.; Petrylak, D. P.; Kalebasty, A. Rezazadeh; Flechon, A.; Jain, R. K.; Gupta, S.; Bupathi, M.; Beuzeboc, P.; Palmbos, P.; V. Balar, A.; Kyriakopoulos, C. E.; Pouessel, D.; Sternberg, C. N.; Tonelli, J.; Sierecki, M.; Zhou, H.; Grivas, P.; Barthelemy, P.; Tagawa, S. T.

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance

EUROPEAN UROLOGY

IF25.2

2024-02-01

OAAI

Sridhar, Srikala S.; Powles, Thomas; Duran, Miguel A. Climent; Park, Se Hoon; Massari, Francesco; Thiery-Vuillemin, Antoine; Valderrama, Begona P.; Ullen, Anders; Tsuchiya, Norihiko; Aragon-Ching, Jeanny B.; Gupta, Shilpa; Petrylak, Daniel P.; Bellmunt, Joaquim; Wang, Jing; Laliberte, Robert J.; di Pietro, Alessandra; Costa, Nuno; Grivas, Petros; Sternberg, Cora N.; Loriot, Yohann

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab 探索未经治疗的局部晚期或转移性尿路上皮癌的新治疗组合: enfortumab vedotin加pembrolizumab

FUTURE ONCOLOGY

IF2.6

2023-11-23

OAAI

Hoimes, Christopher J.; Flaig, Thomas W.; Milowsky, Matthew, I; Friedlander, Terence W.; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R.; Mckay, Rana R.; Petrylak, Daniel P.; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E.

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

ANNALS OF ONCOLOGY

IF65.4

2023-11-01

OAAI

Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. -L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; Wu, C.; Matsangou, M.; Campbell, M.; Petrylak, D. P.

Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Petrylak, D. P.; Garmezy, B.; Shen, J.; Kalebasty, A. Rezazadeh; Sartor, O.; Dreicer, R.; Agarwal, N.; Hussain, M.; Percent, I.; Heath, E.; Gedrich, R.; Yu, T.; Healey, D.; Parameswaran, J.; Sternberg, C. N.; Gao, X.

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2023-10-01

PREAI

Lu, Yi-Tsung; Plets, Melissa; Morrison, Gareth; Cunha, Alexander T.; Cen, Steven Y.; Rhie, Suhn K.; Siegmund, Kimberly D.; Daneshmand, Siamak; Quinn, David I.; Meeks, Joshua J.; Lerner, Seth P.; Petrylak, Daniel P.; Mcconkey, David; Flaig, Thomas W.; Thompson Jr, Ian M.; Goldkorn, Amir

Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; Barata, P. M. Coelho; Hwang, C.; Cruz-Correa, M.; Iafolla, M.; Mckean, M.; Dreicer, R.; Brancato, S.; Lukas, J. J.; Yu, Y.; Moon, H.

研究方向